![Pharmaceuticals | Free Full-Text | New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress Pharmaceuticals | Free Full-Text | New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress](https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-14-01023/article_deploy/html/images/pharmaceuticals-14-01023-g002.png?1633690063)
Pharmaceuticals | Free Full-Text | New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress
![Pharmaceuticals | Free Full-Text | New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress Pharmaceuticals | Free Full-Text | New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress](https://www.mdpi.com/pharmaceuticals/pharmaceuticals-14-01023/article_deploy/html/images/pharmaceuticals-14-01023-g001.png)
Pharmaceuticals | Free Full-Text | New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress
![Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors | Journal of Medicinal Chemistry Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.5b01514/asset/images/large/jm-2015-01514u_0028.jpeg)